Cargando…
Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action
Until the COVID-19 pandemic, San Francisco’s hepatitis C virus (HCV) elimination initiative, End Hep C SF, was expanding and refining HCV testing and treatment strategies citywide, making progress toward local HCV elimination goals. Although a shelter-in-place health order issued in March 2020 categ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257501/ https://www.ncbi.nlm.nih.gov/pubmed/35403488 http://dx.doi.org/10.1177/00333549221083741 |
_version_ | 1784741354350313472 |
---|---|
author | Facente, Shelley N. Grinstein, Rachel Broussard, Janessa Shost, Jessica Azari, Soraya Siruno, Jennifer Jimenez, Jose A. Luetkemeyer, Anne F. Burk, Katie |
author_facet | Facente, Shelley N. Grinstein, Rachel Broussard, Janessa Shost, Jessica Azari, Soraya Siruno, Jennifer Jimenez, Jose A. Luetkemeyer, Anne F. Burk, Katie |
author_sort | Facente, Shelley N. |
collection | PubMed |
description | Until the COVID-19 pandemic, San Francisco’s hepatitis C virus (HCV) elimination initiative, End Hep C SF, was expanding and refining HCV testing and treatment strategies citywide, making progress toward local HCV elimination goals. Although a shelter-in-place health order issued in March 2020 categorized HCV testing as an “essential service,” most HCV testing and treatment immediately stopped until COVID-19–safe protocols could be implemented. During the 14 months of pandemic-related organizational closures, End Hep C SF transitioned to a 100% virtual model, maintaining regularly scheduled meetings. Community-based HCV antibody testing decreased 80% from February to April 2020, and HCV treatment initiation also decreased, although both services started to rebound in mid-to-late 2020, partially as a result of End Hep C SF collaborations. End Hep C SF service providers, clinicians, and advocates reported that the continuous communication and common agenda of End Hep C SF—2 principles of the collective impact initiative—served as a familiar touchpoint and helpful source of information during this isolating and uncertain time. Ultimately, End Hep C SF allowed us to continue HCV elimination strategies through 6 lessons learned: maintaining HCV treatment access through telehealth and mobile services; leveraging research studies that provided HCV testing and treatment; offering HCV screening and linkage to care in tandem with COVID-19–related initiatives; being flexible and inventive, such as administering HCV treatment to residents of shelter-in-place hotels; establishing a data dashboard to track HCV testing and treatment; and relying on partnerships to solve problems and avoid burnout. |
format | Online Article Text |
id | pubmed-9257501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-92575012022-11-28 Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action Facente, Shelley N. Grinstein, Rachel Broussard, Janessa Shost, Jessica Azari, Soraya Siruno, Jennifer Jimenez, Jose A. Luetkemeyer, Anne F. Burk, Katie Public Health Rep Case Study Until the COVID-19 pandemic, San Francisco’s hepatitis C virus (HCV) elimination initiative, End Hep C SF, was expanding and refining HCV testing and treatment strategies citywide, making progress toward local HCV elimination goals. Although a shelter-in-place health order issued in March 2020 categorized HCV testing as an “essential service,” most HCV testing and treatment immediately stopped until COVID-19–safe protocols could be implemented. During the 14 months of pandemic-related organizational closures, End Hep C SF transitioned to a 100% virtual model, maintaining regularly scheduled meetings. Community-based HCV antibody testing decreased 80% from February to April 2020, and HCV treatment initiation also decreased, although both services started to rebound in mid-to-late 2020, partially as a result of End Hep C SF collaborations. End Hep C SF service providers, clinicians, and advocates reported that the continuous communication and common agenda of End Hep C SF—2 principles of the collective impact initiative—served as a familiar touchpoint and helpful source of information during this isolating and uncertain time. Ultimately, End Hep C SF allowed us to continue HCV elimination strategies through 6 lessons learned: maintaining HCV treatment access through telehealth and mobile services; leveraging research studies that provided HCV testing and treatment; offering HCV screening and linkage to care in tandem with COVID-19–related initiatives; being flexible and inventive, such as administering HCV treatment to residents of shelter-in-place hotels; establishing a data dashboard to track HCV testing and treatment; and relying on partnerships to solve problems and avoid burnout. SAGE Publications 2022-04-09 /pmc/articles/PMC9257501/ /pubmed/35403488 http://dx.doi.org/10.1177/00333549221083741 Text en © 2022, Association of Schools and Programs of Public Health |
spellingShingle | Case Study Facente, Shelley N. Grinstein, Rachel Broussard, Janessa Shost, Jessica Azari, Soraya Siruno, Jennifer Jimenez, Jose A. Luetkemeyer, Anne F. Burk, Katie Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title | Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title_full | Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title_fullStr | Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title_full_unstemmed | Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title_short | Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action |
title_sort | hepatitis c elimination during a global pandemic: a case study of resilience in action |
topic | Case Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257501/ https://www.ncbi.nlm.nih.gov/pubmed/35403488 http://dx.doi.org/10.1177/00333549221083741 |
work_keys_str_mv | AT facenteshelleyn hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT grinsteinrachel hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT broussardjanessa hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT shostjessica hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT azarisoraya hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT sirunojennifer hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT jimenezjosea hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT luetkemeyerannef hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction AT burkkatie hepatitisceliminationduringaglobalpandemicacasestudyofresilienceinaction |